


# Reversing the detrimental gene expression in pNF by integrated drug screen mining

--Prediction and validation



Team: **NF-Buster**

# 2022 Hack for NF

---


- Team name: **NF-Buster**
- Project title: **Reversing the detrimental gene expression in pNF by integrated drug screen mining**
- We take on challenge #3 and do a datamining on plexiform neurofibromas drug screen data.  
<https://github.com/yunguangsun/hack4nf2022>
- We want to compete for “Best Use of Data”, “Best project page” and “Challenge winner”
- Team members: Kathy Sun (Researcher, High School Student)  
Yunguang Sun (Researcher, Data Scientist)

# Our considerations in the drug screen challenge:



---

- Potential drug response bias from screening data
  - Genetic discrepancy in pNF cell lines with human *TERT* or mouse *CDK4*
  - Transcriptome drift between physiological condition and cell culture
- Library of Integrated Network-Based Cellular Signatures (LINCS) database
  - Integrated the gene expression and drug response data
  - More than 54,000 small compounds in tumor drug screening
  - 431 Datasets and 353 Cell Lines
  - 4082 Gene over-expressions, 1113059 Signatures
- Reverse the highly expressed gene expression in pNF to inhibit tumor growth
  - Prioritize the drug candidates in LINCS by determine scores of Reversal of Gene Expression Signatures (sRGES)
  - Use pNF cell line drug screen as experimental validations for the predicted drug candidates

# Let's go fishing



We hypothesize that decreasing the highly expressed genes in tumors will inhibit the pNF growth



# Top drug Candidates for NF1 from Team NF-Buster:

## We have 22 distinct drugs and 169 targets

	drug_name	median_response	hugo_gene	std_name	pert_iname	sRGES
1	NCGC00250406-01	43.98139723	FNTA	TIPIFARNIB	tipifarnib	-0.245848822
3	NCGC00262603-01	44.75736189	PIK3CB	IDELALISIB	idelalisib	-0.229061682
8	NCGC00168110-01	46.94346416	AAK1	TOZASERTIB	tozasertib	-0.238526074
82	NCGC00346508-01	46.9546487	DCK	TG100-115	TG100-115	-0.523947529
83	NCGC00346877-01	48.10236892	ADAM17	BATIMASTAT	batimastat	-0.215815757
90	NCGC00263539-03	48.35751978	ADRA1A	ZIPRASIDONE	ziprasidone	-0.207924917
112	NCGC00016759-03	48.87592645	AKR1C3	NAPROXEN	naproxen	-0.284358613
114	NCGC00094818-08	49.86684411	TDP1	HEXESTROL	hexestrol	-0.20074983
115	NCGC00159453-06	50.23976884	EPHX2	ZILEUTON	zileuton	-0.24721922
117	NCGC00016311-16	50.55306749	ADRA1A	PHENTOLAMINE	phentolamine	-0.225438256
124	NCGC00159509-02	50.74462695	ACE	PERINDOPRIL	perindopril	-0.209761043
125	NCGC00016268-09	51.19216213	HCAR2	NIACIN	niacin	-0.213302736
126	NCGC00015439-06	51.3509198	GABRA1	FLUMAZENIL	flumazenil	-0.216771654
131	NCGC00164619-04	51.62238074	CYP19A1	ANASTROZOLE	anastrozole	-0.602553876
132	NCGC00021146-06	51.63304745	ADORA3	KETANSERIN	ketanserin	-0.222011256
135	NCGC00168781-01	51.65878703	PDE11A	TADALAFIL	tadalafil	-0.223077039
137	NCGC00167781-07	51.71523734	HRH1	CETIRIZINE	cetirizine	-0.255861124
138	NCGC00164549-01	52.47023255	KCNH2	DOFETILIDE	dofetilide	-0.542226678
139	NCGC00096077-05	52.90058534	ADRA1A	OLANZAPINE	olanzapine	-0.382206228
166	NCGC00167531-03	53.01633198	BCHE	RIVASTIGMINE	rivastigmine	-0.349656807
167	NCGC00014670-16	53.40765291	DRD3	DOMPERIDONE	domperidone	-0.239881158
169	NCGC00178734-03	55.72963108	DPP4	SITAGLIPTIN	sitagliptin	-0.432513651

### Top 5 winners:

1. Protein farnesyltransferase/geranylgeranyltransferase
2. Pi3K kinase
3. AP2 Kinase 1
4. Deoxycytidylate kinase
5. A disintegrin and metalloprotease 17

# Future Directions

---

- Collect and accumulate more relevant gene expression datasets from pNF1 in vivo progression specimen to establish more biological relevant gene expression changes
- Collection of experimental drug test data from various sources related to pNF1 especially *in vivo*
- Ranking and prioritizing promising drug candidates using more relevant differentially expressed genes in more biological screening data
- Validate top 5 drug candidates in pNF1 cell lines and further validate 1 to 2 more effective drugs *in vivo*

## References:

---

- Zeng, B., Glicksberg, B.S., Newbury, P. *et al.* OCTAD: an open workspace for virtually screening therapeutics targeting precise cancer patient groups using gene expression features. *Nat Protoc* **16**, 728–753 (2021). <https://doi.org/10.1038/s41596-020-00430-z>
- Brown, R.M.; Farouk Sait, S.; Dunn, G.; Sullivan, A.; Bruckert, B.; Sun, D. Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas. *Brain Sci.* **2022**, *12*, 720. <https://doi.org/10.3390/brainsci12060720>
- The slack discussions in the general and scientific channels
- The R codes provided by the NFHackathon organizers




# Acknowledgements

---

- Public datasets:
  - GSE14038 (syn5950004)
  - Syn20700260
  - LINCS
  - syn17091507
  - GTEx (Genotype-Tissue Expression)
  - TARGET (Therapeutically Applicable Research to Generate Effective Treatments)
  - TCGA (The Cancer Genome Atlas)
- The teamwork among the NFhackathon community
- Promote awareness of pNF in our new generations

# Thank you for listening!



Team: **NF-Buster**